Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)'s stock price gapped down before the market opened on Thursday following insider selling activity. The stock had previously closed at $35.05, but opened at $33.94. Y-mAbs Therapeutics shares last traded at $34.84, with a volume of 1,901 shares. Specifically, Director Biotech Aps Wg sold 116,700 shares of the stock in a transaction on Wednesday, June 9th. The stock was sold at an average price of $36.19, for a total transaction of $4,223,373.00. Following the transaction, the director now owns 4,306,394 shares of the company's stock, valued at approximately $155,848,398.86. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Thomas Gad sold 7,000 shares of the stock in a transaction on Monday, April 26th. The stock was sold at an average price of $27.96, for a total value of $195,720.00. Following the transaction, the insider now directly owns 7,000 shares in the company, valued at approximately $195,720. The disclosure for this sale can be found here. In the last three months, insiders have sold 290,471 shares of company stock worth $10,171,239. Corporate insiders own 38.40% of the company's stock.
Several brokerages recently weighed in on YMAB. Bank of America raised Y-mAbs Therapeutics from a "neutral" rating to a "buy" rating in a research report on Friday, May 7th. Zacks Investment Research lowered Y-mAbs Therapeutics from a "hold" rating to a "sell" rating in a research report on Tuesday, July 13th. HC Wainwright reaffirmed a "buy" rating and issued a $68.00 target price on shares of Y-mAbs Therapeutics in a research report on Wednesday, July 7th. Finally, Wedbush cut their target price on Y-mAbs Therapeutics from $67.00 to $52.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 21st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of "Buy" and a consensus price target of $54.13.
The business's fifty day simple moving average is $34.42.
Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Thursday, May 6th. The company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.14. The company had revenue of $5.38 million during the quarter, compared to analyst estimates of $35.67 million. On average, equities analysts anticipate that Y-mAbs Therapeutics, Inc. will post -1.29 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently made changes to their positions in YMAB. Teachers Retirement System of The State of Kentucky grew its stake in shares of Y-mAbs Therapeutics by 24.7% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 25,674 shares of the company's stock valued at $776,000 after acquiring an additional 5,090 shares in the last quarter. Squarepoint Ops LLC grew its stake in shares of Y-mAbs Therapeutics by 87.1% during the first quarter. Squarepoint Ops LLC now owns 36,889 shares of the company's stock valued at $1,116,000 after acquiring an additional 17,174 shares in the last quarter. Millennium Management LLC grew its stake in shares of Y-mAbs Therapeutics by 171.2% during the first quarter. Millennium Management LLC now owns 284,888 shares of the company's stock valued at $8,615,000 after acquiring an additional 179,831 shares in the last quarter. Voloridge Investment Management LLC acquired a new stake in shares of Y-mAbs Therapeutics during the first quarter valued at about $393,000. Finally, First Light Asset Management LLC grew its stake in shares of Y-mAbs Therapeutics by 48.5% during the first quarter. First Light Asset Management LLC now owns 944,253 shares of the company's stock valued at $28,554,000 after acquiring an additional 308,601 shares in the last quarter. Hedge funds and other institutional investors own 60.77% of the company's stock.
Y-mAbs Therapeutics Company Profile (NASDAQ:YMAB)
Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.
Featured Story: What is total return in investing?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: Options Trading - Understanding Strike Price7 Healthcare Stocks Delivering Innovation in 2021
We all knew that traditional healthcare services were disrupted in 2020. The patient-doctor relationship went virtual. In the early months of the pandemic, many people in need of elective surgeries simply did not have that option available to them. And even local pharmacies took on a new e-commerce role as curbside pickup or home delivery of prescription medication became the norm.
Not surprisingly healthcare stocks were battered last year. Overall, the sector was down 11%, far below the S&P 500 Index that climbed over 15%.
However, the market is always forward-looking with a particular eye towards innovation. The healthcare sector has many companies that are developing innovative approaches in areas such as gene editing. And other companies are in late-stage trials for drugs that can deliver breakthrough results for conditions that continue to plague our world.
That’s the focus of this presentation. We’ve identified 7 healthcare stocks that are delivering innovative ideas that will help deliver better patient outcomes. And in some cases will revolutionize medicine altogether. These are also the stocks that analysts have their eye on.
View the "7 Healthcare Stocks Delivering Innovation in 2021"